XTalks

NOVEMBER 12, 2024

Moreover, in low- and middle-income countries, lack of healthcare access increases the disease’s impact, as limited diagnostics, vaccination coverage and medical resources limit early detection and treatment. These therapies work by controlling excessive inflammatory responses in the lungs.

Bacteria 110

Bacteria Life Science Vaccine Vaccination 110

World of DTC Marketing

AUGUST 21, 2020

million people have been infected and over 165,000 have died, the promise of a vaccine is hampered by a vexing epidemic that long preceded Covid-19: obesity. The finding was replicated in a follow-up study that used longer needles to ensure the vaccine was injected into muscle and not fat. In the United States, where at least 4.6

Immune Response 238

Immune Response Vaccine Vaccination Scientist 238

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

Pharmaceutical Technology

NOVEMBER 20, 2022

Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. The vaccine is indicated for active immunisation to prevent the disease.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. Other efforts to develop a nasally-delivered COVID-19 vaccine have met with greater success.

Vaccine 116

Vaccine Vaccination Immune Response Development 116

Pharma Mirror

OCTOBER 16, 2023

The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021. The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021.

Immune Response 130

Immune Response Drugs Protein Vaccination 130

pharmaphorum

JUNE 21, 2021

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. Efficacy was assessed in a subset of 42 patients treated with the shot as a monotherapy or alongside an anti-PD-1 drug.

Vaccine 145

Vaccine Vaccination Immune Response Trials 145

XTalks

JANUARY 8, 2021

The US Food and Drug Administration (FDA) released a statement this week about dosing schedules for COVID-19 vaccines, saying that any dose changes would be premature. The FDA therefore continues to recommend the two-dose regimens that both the BioNTech/Pfizer and Moderna vaccines require.

Vaccine 144

Vaccine Vaccination Clinical Trials Clinical Trials 144

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. over the last five years. A broad front.

Vaccine 134

Vaccine Vaccination Clinical Trials Clinical Trials 134

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. .

Vaccine 98

Vaccine Vaccination Trials Immune Response 98

pharmaphorum

JANUARY 12, 2021

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. Non-injectables remove the need for health professional-led immunisation programmes, making widespread vaccine roll-outs quicker and easier and more affordable,” Channon told pharmaphorum.

Licensing 119

Licensing Licensing Vaccine Vaccination 119

Pharmaceutical Technology

APRIL 11, 2023

The US Food and Drug Administration (FDA) has granted final approval to India-based Zydus Lifesciences ‘ 500mg azithromycin tablets for the treatment of bacterial infections. Zydus will manufacture the drug at its formulation facility in Moraiya, Ahmedabad, in the Indian state of Gujarat.

FDA Approval 130

FDA Approval Drugs Immune Response Manufacturing 130

pharmaphorum

JANUARY 8, 2021

The Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in the UK and South Africa, according to research from the drugs giant. The study team tested blood taken from people who had received the mRNA vaccine developed by BioNTech and Pfizer.

Scientist 124

Scientist Vaccine Vaccination Immune Response 124

pharmaphorum

JULY 6, 2021

A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. ” The anti-HER2 market is advancing rapidly however, with a new generation of drugs coming through the industry pipeline.

Vaccine 119

Vaccine Vaccination Trials Antibody 119

NY Times

MARCH 23, 2022

The company said the vaccine produced a strong immune response in children younger than 6, but proved only about 40 percent effective in preventing symptomatic Covid-19.

Vaccine 94

Vaccine Vaccination Immune Response Clinical Trials 94

Pharmaceutical Technology

AUGUST 26, 2022

Amid a shortage of monkeypox vaccine doses, the WHO and FDA have declared public health emergencies, and the FDA has granted its first Emergency Use Authorization (EUA) to a monkeypox vaccine and opened the door for more. On the same day, the FDA granted a EUA to Bavarian Nordic’s (Copenhagen, Denmark) Jynneos vaccine.

Vaccine 130

Vaccine Vaccination Immune Response Manufacturing 130

XTalks

NOVEMBER 5, 2024

Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Production 100

Production Vaccine Vaccination Immune Response 100

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Production 100

Production Vaccine Vaccination Immune Response 100

XTalks

APRIL 26, 2021

After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease.

Vaccine 105

Vaccine Vaccination Immune Response Trials 105

Scienmag

JANUARY 26, 2022

WHAT: In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the Food and Drug Administration (FDA), an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The […]. (..)

Vaccine 84

Vaccine Vaccination Immune Response Trials 84

pharmaphorum

OCTOBER 5, 2022

million grant by the US government to develop an intranasal vaccine for gonorrhoea, a sexually-transmitted infection that is on the rise around the world. Some gonorrhoea infections have become untreatable with all seven main antibiotic classes – a situation last encountered in the 1920s before the advent of effective drugs for the bacterium.

Vaccine 98

Vaccine Vaccination Immune Response Bacterium 98

XTalks

JUNE 21, 2024

The US Food and Drug Administration (FDA) has green-lighted the first pneumonia vaccine specifically designed for adults 50 years of age and older. These numbers do not reflect the efficacies of the vaccines, which have not been compared head-to-head in any trial yet.

FDA Approval 108

FDA Approval Vaccine Vaccination Life Science 108

NY Times

MAY 11, 2022

Antibody levels rose in the children who received it, suggesting the vaccine protects against infection. But the data were gathered before the arrival of Omicron.

Immune Response 62

Immune Response Vaccine Vaccination Antibody 62

pharmaphorum

AUGUST 16, 2020

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. The EU says its advance purchase order will finance part of the upfront costs of developing the vaccine.

Vaccine 111

Vaccine Vaccination Immune Response Trials 111

pharmaphorum

NOVEMBER 25, 2021

The first patients are now being treated as part of a first-in-human trial of a vaccine, administered as a nasal spray, that aims to slow down the progression of Alzheimer’s disease (AD). Meanwhile researchers in Japan are also running preclinical studies of an intranasal tau vaccine.

Vaccine 98

Vaccine Vaccination Trials Immune Response 98

XTalks

JUNE 24, 2022

The US Food and Drug Administration (FDA) has authorized the use of Pfizer-BioNTech’s and Moderna’s COVID-19 vaccines for children as young as six months old, a much-awaited decision for some parents with young children. The vaccine had been authorized for use in adults 18 years of age and older. Califf, MD.

Vaccine 98

Vaccine Vaccination Immune Response Trials 98

Pharmaceutical Technology

AUGUST 18, 2022

New Zealand’s Medsafe has granted expanded provisional approval for Novavax ’s protein-based Covid-19 vaccine Nuvaxovid (NVX-CoV2373) as a heterologous and homologous booster dose in adults aged 18 years and above. The booster vaccine is indicated for active immunisation for the prevention of Covid-19 in people of this age group.

Immune Response 130

Immune Response Vaccine Vaccination Protein 130

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. This is seven more strains than its current winning vaccine Prevnar 13, which registered $5.95

FDA Approval 89

FDA Approval Vaccine Vaccination Immune Response 89

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef.

Vaccine 111

Vaccine Vaccination Protein Immune Response 111

The Pharma Data

MAY 17, 2021

The investigational COVID-19 vaccine uses the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines, along with GSK’s established pandemic adjuvant technology. response in the over-50s, the age group deemed at higher risk for contracting the severe form of the virus. . Phase 2 study ?.

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

pharmaphorum

SEPTEMBER 24, 2020

The UK could be the first country to carry out a COVID-19 “challenge trial” where healthy volunteers are deliberately infected with coronavirus to test vaccines, according to press reports. That vaccine is top of the World Health Organization’s list of vaccines in clinical development, which shows there are 38 potential shots in human trials.

Vaccine 98

Vaccine Vaccination Trials Immune Response 98

pharmaphorum

DECEMBER 6, 2022

Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent despite centring on their mRNA-based vaccines for COVID-19. It also waived its rights to bring the lawsuit when it pledged not to sure other COVID-19 vaccine producers during the pandemic, according to Reuters.

Vaccine 97

Vaccine Vaccination Immune Response Sales 97

Scienmag

SEPTEMBER 21, 2020

September 21, 2020–(BRONX, NY)–The first study comparing the immune responses of adults and children with COVID-19 has detected key differences that may contribute to understanding why children usually have milder disease than adults. The study was published today in Science […].

Immune Response 48

Immune Response Vaccination Vaccine Development 48

The Pharma Data

JULY 11, 2021

Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi ® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers.

Immune Response 52

Immune Response Vaccine Vaccination Licensing 52

Camargo

JULY 27, 2021

Gene therapy, which was in its infancy around 30 years ago, is now becoming a more prominent treatment method in many therapeutic areas, from personalized therapy to mass vaccinations against COVID-19. Exposure-Response Considerations. However, dose selection in such cases is quite complicated and frequently limited to one attempt.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

XTalks

AUGUST 16, 2021

The US Food and Drug Administration (FDA) has amended its emergency use authorizations (EUA) for both the Pfizer and Moderna COVID-19 vaccines to incorporate a third dose for immunocompromised individuals. The allowance of a booster dose only applies to immunocompromised individuals. According to the CDC, approximately 2.7

Vaccine 104

Vaccine Vaccination Antibody Immune Response 104